5:45 PM
 | 
Oct 16, 2012
 |  BC Extra  |  Company News

Isis falls on mipomersen briefing docs

Isis Pharmaceuticals Inc. (NASDAQ:ISIS) fell $2.88 (22%) to $10.27 on Tuesday after FDA reviewers raised several safety concerns in briefing documents for mipomersen to treat homozygous familial hypercholesterolemia (hoFH), including a higher rate of neoplasms compared to placebo (3.1% vs. 0.9%). Reviewers said the imbalance will need to be assessed further, noting that there are "several confounding...

Read the full 271 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >